Business Wire

CA-QUANTA-CLOUD-TECH

26.8.2021 15:02:11 CEST | Business Wire | Press release

Share
QCT Showcases Advanced 5G Solutions at The Big 5G Event

Quanta Cloud Technology (QCT), a leading data center hardware solution provider, today announced details around its participation at the Big 5G Event 2021 , being held onsite as well as virtually from August 30 – September 3, at the Colorado Convention Center, Denver. QCT will showcase 5G demos and solutions developed alongside ecosystem partners (Intel, Red Hat, Robin.io, Wind River, DZS) at Booth #900a for both public and private networks and share their latest insights at the event.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210826005348/en/

QCT 5G Demos, Solutions, and Partner Highlights at the Big 5G Event:

QCT 5G solutions span data center and edge, to on-premise, with two major product lines, IronInfra and OmniPOD , to address infrastructure modernization and digital transformation needs.

  • IronInfra Product Line : QCT provides IronCloud and IronEdge solutions for telecom infrastructures.
    • IronCloud - Network Function Virtualization Infrastructure (NFVI) solutions for telecom operators. QCT IronCloud provides cloud native infrastructures for mobile network operators running 5G core, vRAN, CNFs, and CDN use cases through its ecosystem partnerships.

    • IronEdge - QCT’s edge solutions that have been approved by the Telecom Infra Project for building and supporting Open RAN in different scenarios, including Centralized RAN, Distributed RAN and MEC use cases.

  • OmniPOD Product Line : End-to-end enterprise 5G network solutions that help achieve the realization of dynamic 5G applications and services.
    • OmniCore : QCT’s cloud-native, virtualized 5G core network solution that features high-availability designs to meet reliability demands and allows for the optimization of network functions.

    • OmniRAN : QCT’s 5G RAN solution consisting of BBU, FHGW, and RRU with flexible system configurations to fulfill diverse coverage and capacity needs.

    • OmniView : QCT’s Operations Administration and Management (OAM) system to manage and monitor OmniCore and OmniRAN.

  • Ecosystem Partner Highlights : Developments alongside the following partners will be on-hand.
    • Intel/Red Hat : QCT builds an Open RAN CU/DU with Red Hat OpenShift, Intel FlexRAN and OpenNESS operator. It achieves automation of installation and configuration and allows easy resource management and monitoring for operators.

    • Robin.io : QCT and Robin.io developed an open and extensible cloud-native automation platform for deployment and lifecycle management of the entire 5G stack, both VNF and CNF with industry leading TCO.

    • Wind River : As a first wave partner to the Wind River Studio Hardware Ready Program, QCT completed self-validation with data center and edge servers which benefit service providers in quickly reducing OPEX while accelerating the introduction of new high-value services.

    • DZS : The QCT and DZS Converged Edge Cloud Blueprints provide simple, easy-to-deploy, jointly validated reference configurations of hardware and software for 5G network services and deployments across the Core, RAN, and Edge Access domains.

QCT experts will be available at Booth #900a to share their 5G journey and deployments for multiple customer POCs across industry verticals such as manufacturing, agriculture, and entertainment. Learn more at: https://go.qct.io/telco/

About Quanta Cloud Technology (QCT)

Quanta Cloud Technology (QCT) is a global data center solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds.

Product lines include hyperconverged and software-defined data center solutions as well as servers, storage, switches and integrated racks with an ecosystem of hardware components and software partners. QCT designs, manufactures, integrates and services its offerings via its own global network. The parent of QCT is Quanta Computer, Inc., a Fortune Global 500 corporation. www.QCT.io

Link:

ClickThru

Social Media:

https://www.facebook.com/quantacloudtechnology?fref=photo

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and

Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye